| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | -0.24% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 01/01/2026 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 01/01/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 19/06/2021 | |
Janis Buks
CHM | Chairman | - | 01/09/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -3.46% | - | - | 148M | |
| +0.15% | +0.75% | +16.13% | +73.62% | 49.38B | |
| +0.97% | +4.92% | +59.35% | +120.29% | 36.35B | |
| +2.50% | +0.84% | -8.10% | +22.65% | 11.87B | |
| -0.81% | -3.84% | +12.15% | +71.62% | 11.53B | |
| +0.38% | +1.16% | +31.33% | +131.86% | 8.99B | |
| +1.80% | +2.35% | +48.24% | -5.38% | 7B | |
| -0.51% | -0.85% | +11.77% | +33.26% | 6.76B | |
| -0.52% | -2.56% | +1.87% | +173.50% | 6.46B | |
| -1.32% | -6.80% | -33.10% | -2.26% | 5.49B | |
| Average | +0.26% | -0.95% | +15.51% | +68.79% | 15.98B | |
| Weighted average by Cap. | +0.49% | +0.32% | +24.52% | +80.53% |
Employees
2,191
Sector
Pharmaceuticals
